Janus kinase inhibitors in rheumatoid arthritis: Clinical applications

Jennifer Walker; Malcolm Smith

doi:10.18773/austprescr.2014.062

Janus kinase inhibitors in rheumatoid arthritis: Clinical applications

Jennifer Walker, Malcolm Smith

Research output: Contribution to journal › Article

4 Citations (Scopus)

Abstract

Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.

Original language	English
Pages (from-to)	158-160
Number of pages	3
Journal	Australian Prescriber
Volume	37
Issue number	5
DOIs	https://doi.org/10.18773/austprescr.2014.062
Publication status	Published - 1 Oct 2014
Externally published	Yes

Bibliographical note

Except where otherwise noted, all articles published in Australian Prescriber can be used under the CC BY-NC-ND licence.

Keywords

Molecular targeted therapy
Tofacitinib
rheumatoid arthritis

Access to Document

10.18773/austprescr.2014.062Licence: CC BY-NC-ND

Walker_Janus_P2014Final published version, 118 KBLicence: CC BY-NC-ND

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Janus kinase inhibitors in rheumatoid arthritis: Clinical applications'. Together they form a unique fingerprint.

Cite this

Walker, J., & Smith, M. (2014). Janus kinase inhibitors in rheumatoid arthritis: Clinical applications. Australian Prescriber, 37(5), 158-160. https://doi.org/10.18773/austprescr.2014.062

@article{77c62756f9f84608a34469adc65761dc,

title = "Janus kinase inhibitors in rheumatoid arthritis: Clinical applications",

abstract = "Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.",

keywords = "Molecular targeted therapy, Tofacitinib, rheumatoid arthritis",

author = "Jennifer Walker and Malcolm Smith",

note = "Except where otherwise noted, all articles published in Australian Prescriber can be used under the CC BY-NC-ND licence.",

year = "2014",

month = oct,

day = "1",

doi = "10.18773/austprescr.2014.062",

language = "English",

volume = "37",

pages = "158--160",

journal = "Australian Prescriber",

issn = "0312-8008",

publisher = "Commonwealth of Australia",

number = "5",

}

TY - JOUR

T1 - Janus kinase inhibitors in rheumatoid arthritis

T2 - Clinical applications

AU - Walker, Jennifer

AU - Smith, Malcolm

N1 - Except where otherwise noted, all articles published in Australian Prescriber can be used under the CC BY-NC-ND licence.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.

AB - Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.

KW - Molecular targeted therapy

KW - Tofacitinib

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84929863904&partnerID=8YFLogxK

U2 - 10.18773/austprescr.2014.062

DO - 10.18773/austprescr.2014.062

M3 - Article

AN - SCOPUS:84929863904

VL - 37

SP - 158

EP - 160

JO - Australian Prescriber

JF - Australian Prescriber

SN - 0312-8008

IS - 5

ER -